Monalizumab

From WikiMD's WELLNESSPEDIA

Monalizumab is a monoclonal antibody used in cancer immunotherapy.

Monalizumab is a monoclonal antibody that targets the NKG2A receptor, which is an inhibitory receptor found on natural killer cells and some T cells. It is being investigated for its potential use in cancer immunotherapy.

Mechanism of Action[edit]

Monalizumab works by blocking the interaction between NKG2A and its ligand, HLA-E. NKG2A is an inhibitory receptor that, when engaged, can dampen the immune response. By inhibiting this interaction, monalizumab can enhance the activity of natural killer cells and T cells, promoting a stronger immune response against cancer cells.

Clinical Development[edit]

Monalizumab is currently undergoing clinical trials to evaluate its efficacy and safety in treating various types of cancer, including head and neck cancer, ovarian cancer, and colorectal cancer. Early studies have shown promise, with some patients experiencing tumor shrinkage and improved survival rates.

Potential Benefits[edit]

The use of monalizumab in cancer therapy offers several potential benefits:

  • Enhanced Immune Response: By blocking the inhibitory signals, monalizumab can potentiate the body's natural immune response against tumors.
  • Combination Therapy: Monalizumab is being studied in combination with other immunotherapies, such as PD-1 inhibitors, to assess synergistic effects.
  • Broad Applicability: The mechanism of action suggests that monalizumab could be effective against a wide range of cancers.

Side Effects[edit]

As with many immunotherapies, monalizumab can cause immune-related side effects. These may include:

  • Fatigue
  • Fever
  • Skin rash
  • Gastrointestinal disturbances

Patients receiving monalizumab are closely monitored for these and other potential adverse effects.

Research and Development[edit]

Monalizumab is being developed by Innate Pharma in collaboration with AstraZeneca. The ongoing research aims to better understand the optimal use of monalizumab in cancer treatment and to identify which patient populations may benefit the most.

Also see[edit]



Immunology
Basics
Immune cells
Immune responses
Immunotherapy
Diagnostic tests
This immunology-related article is a stub.



Cancer treatment
General treatments
Surgical methods
Radiation therapies
Chemotherapy types
Targeted therapies
This Cancer related article is a stub.

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Monalizumab&oldid=6285237"